Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Holen KD"'
Publikováno v:
Drug Designing: Open Access.
Finding the maximum tolerated dose (MTD) is the most important primary objective for Phase I oncology studies. The drug exposure and the toxicity event are the two components required for characterization of the MTD. Phase I trials currently require
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
New England Journal of Medicine. 4/23/2009, Vol. 360 Issue 17, p1790-1792. 3p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Gan HK; Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia hui.gan@onjcri.org.au.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Medicine, University of Melbourne, Melbourne, Australia., Burge M; Royal Brisbane and Women's Hospital, Brisbane, Australia.; University of Queensland, Brisbane, Australia., Solomon B; Department of Medicine, University of Melbourne, Melbourne, Australia.; Peter MacCallum Cancer Centre, Melbourne, Australia., Lee ST; Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia., Holen KD; AbbVie, North Chicago, Illinois; and., Zhang Y; Sinotau Pharmaceutical Group, Beijing, China., Ciprotti M; Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia., Lee FT; Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia., Munasinghe W; AbbVie, North Chicago, Illinois; and., Fischer J; AbbVie, North Chicago, Illinois; and., Ansell P; AbbVie, North Chicago, Illinois; and., Fox G; AbbVie, North Chicago, Illinois; and., Xiong H; AbbVie, North Chicago, Illinois; and., Reilly EB; AbbVie, North Chicago, Illinois; and., Humerickhouse R; AbbVie, North Chicago, Illinois; and., Scott AM; Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Medicine, University of Melbourne, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2021 Jun 01; Vol. 62 (6), pp. 787-794. Date of Electronic Publication: 2021 Jan 28.
Autor:
Lassman AB; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York. ABL7@cumc.columbia.edu., Roberts-Rapp L; AbbVie, Inc., North Chicago, Illinois., Sokolova I; Abbott Molecular, Inc., Des Plaines, Illinois., Song M; Abbott Molecular, Inc., Des Plaines, Illinois., Pestova E; Abbott Molecular, Inc., Des Plaines, Illinois., Kular R; Abbott Molecular, Inc., Des Plaines, Illinois., Mullen C; Abbott Molecular, Inc., Des Plaines, Illinois., Zha Z; AbbVie, Inc., North Chicago, Illinois., Lu X; AbbVie, Inc., North Chicago, Illinois., Gomez E; AbbVie, Inc., North Chicago, Illinois., Bhathena A; AbbVie, Inc., North Chicago, Illinois., Maag D; AbbVie, Inc., North Chicago, Illinois., Kumthekar P; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Gan HK; Austin Health, Olivia Newton-John Cancer Research Institute, and La Trobe University, Melbourne, Victoria, Australia., Scott AM; Austin Health, Olivia Newton-John Cancer Research Institute, and La Trobe University, Melbourne, Victoria, Australia., Guseva M; AbbVie, Inc., North Chicago, Illinois., Holen KD; AbbVie, Inc., North Chicago, Illinois., Ansell PJ; AbbVie, Inc., North Chicago, Illinois., van den Bent MJ; Erasmus MC Cancer Center, Rotterdam, the Netherlands.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Jun 01; Vol. 25 (11), pp. 3259-3265. Date of Electronic Publication: 2019 Feb 22.
Autor:
Lassman AB; Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA., van den Bent MJ; Erasmus MC Cancer Institute, Rotterdam, Netherlands., Gan HK; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.; Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia., Reardon DA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Kumthekar P; Northwestern University, Chicago, Illinois, USA., Butowski N; Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA., Lwin Z; Department of Medical Oncology, University of Queensland School of Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia., Mikkelsen T; Henry Ford Health System, Detroit, Michigan, USA., Nabors LB; University of Alabama at Birmingham, Birmingham, Alabama, USA., Papadopoulos KP; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, USA., Penas-Prado M; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Simes J; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Wheeler H; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Walbert T; Henry Ford Health System, Detroit, Michigan, USA., Scott AM; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.; Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia., Gomez E; AbbVie Inc., North Chicago, Illinois, USA., Lee HJ; AbbVie Inc., North Chicago, Illinois, USA., Roberts-Rapp L; AbbVie Inc., North Chicago, Illinois, USA., Xiong H; AbbVie Inc., North Chicago, Illinois, USA., Ansell PJ; AbbVie Inc., North Chicago, Illinois, USA., Bain E; AbbVie Inc., North Chicago, Illinois, USA., Holen KD; AbbVie Inc., North Chicago, Illinois, USA., Maag D; AbbVie Inc., North Chicago, Illinois, USA., Merrell R; NorthShore University Health System, Evanston, Illinois, USA.
Publikováno v:
Neuro-oncology [Neuro Oncol] 2019 Jan 01; Vol. 21 (1), pp. 106-114.
Autor:
Gan HK; Department of Medical Oncology, Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University School of Cancer Medicine, Melbourne, Victoria, Australia.; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia., Reardon DA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Lassman AB; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA., Merrell R; Department of Neurology, NorthShore University HealthSystem, Evanston, Illinois, USA., van den Bent M; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands., Butowski N; Department of Neurological Surgery, University of California, San Francisco, California, USA., Lwin Z; Department of Medical Oncology, University of Queensland School of Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia., Wheeler H; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Fichtel L; South Texas Accelerated Research Therapeutics, San Antonio, Texas, USA., Scott AM; Department of Medical Oncology, Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University School of Cancer Medicine, Melbourne, Victoria, Australia.; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia., Gomez EJ; AbbVie Inc., North Chicago, Illinois, USA., Fischer J; AbbVie Inc., North Chicago, Illinois, USA., Mandich H; AbbVie Inc., North Chicago, Illinois, USA., Xiong H; AbbVie Inc., North Chicago, Illinois, USA., Lee HJ; AbbVie Inc., North Chicago, Illinois, USA., Munasinghe WP; AbbVie Inc., North Chicago, Illinois, USA., Roberts-Rapp LA; AbbVie Inc., North Chicago, Illinois, USA., Ansell PJ; AbbVie Inc., North Chicago, Illinois, USA., Holen KD; AbbVie Inc., North Chicago, Illinois, USA., Kumthekar P; Department of Neurology, Northwestern University, Chicago, Illinois, USA.
Publikováno v:
Neuro-oncology [Neuro Oncol] 2018 May 18; Vol. 20 (6), pp. 838-847.
Autor:
Goss GD; The Ottawa Hospital Research Institute and the University of Ottawa, Ottawa, Ontario, Canada., Vokes EE; Department of Medicine, University of Chicago, Chicago, Illinois., Gordon MS; HonorHealth Research Institute, Scottsdale, Arizona., Gandhi L; New York University Perlmutter Cancer Center, NYU Health, New York, New York., Papadopoulos KP; South Texas Accelerated Research Therapeutics, San Antonio, Texas., Rasco DW; South Texas Accelerated Research Therapeutics, San Antonio, Texas., Fischer JS; AbbVie, Inc, North Chicago, Illinois., Chu KL; AbbVie, Inc, North Chicago, Illinois., Ames WW; AbbVie, Inc, North Chicago, Illinois., Mittapalli RK; AbbVie, Inc, North Chicago, Illinois., Lee HJ; AbbVie, Inc, North Chicago, Illinois., Zeng J; AbbVie, Inc, North Chicago, Illinois., Roberts-Rapp LA; AbbVie, Inc, North Chicago, Illinois., Loberg LI; AbbVie, Inc, North Chicago, Illinois., Ansell PJ; AbbVie, Inc, North Chicago, Illinois., Reilly EB; AbbVie, Inc, North Chicago, Illinois., Ocampo CJ; AbbVie, Inc, North Chicago, Illinois., Holen KD; AbbVie, Inc, North Chicago, Illinois., Tolcher AW; South Texas Accelerated Research Therapeutics, San Antonio, Texas.
Publikováno v:
Cancer [Cancer] 2018 May 15; Vol. 124 (10), pp. 2174-2183. Date of Electronic Publication: 2018 Mar 13.